Genprex Study Links Reqorsa Gene Therapy to Cellular Repair Pathways in Lung Cancer Patients
Bitget2026/11/05 12:07- Genprex on Nov. 5, 2026, announced a patient analysis linking its experimental Reqorsa gene therapy to cellular repair processes associated with aging.
- The analysis covered 11 lung cancer patients in two clinical trials, showing a shift from an early immune response toward cellular maintenance.
- Results were presented at the Gerontological Society of America meeting, held Nov. 4-7, 2026, in National Harbor, Maryland.
- The findings support research into Reqorsa’s potential beyond oncology but do not establish an anti-aging benefit.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
